While Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding steady with several other vaccine launches underway around the world.

hubs.li/Q04DD1Xh0

Voyager Therapeutics cut an undisclosed number of jobs in Q3 to reduce operating expenses and extend its cash runway. C4 Therapeutics also reduced its research headcount this year, though it did not say when the layoffs occurred or how many were affected.

hubs.li/Q04DBCM80

The BioSpace 40 Under 40 honoree helped steer Forge’s sale to Ajinomoto. Now, Samantha Piteri-Molina sees opportunities in AI-driven analytics and Ohio’s gene therapy ecosystem—with a responsibility to patients worldwide.

hubs.li/Q04DBn2d0

After the FDA delayed a decision for Agios Pharmaceuticals’ sickle cell disease candidate, the biopharma is letting go of more than 35% of its R&D employees.

hubs.li/Q04DzMcN0

Sarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.

hubs.li/Q04DzLqf0

Also lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.

hubs.li/Q04DznZm0

Personalized cancer vaccines are getting closer to market. Merck and Moderna just showed successful manufacturing in a large Phase 3 trial, proving they can deliver the goods.

hubs.li/Q04DzgVX0

Advocates are sounding the alarm on social media as they learn from their doctors that Novartis has received reports of tumors in patients who have been treated with the spinal muscular atrophy gene therapy.

hubs.li/Q04DtHSW0

Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter.

hubs.li/Q04DrMVP0

With backing from three Big Pharma investment arms, British biotech T-Therapeutics is brewing up a clinical launch for its cancer and autoimmune T cell engagers.

hubs.li/Q04Drr060

Avidity Biosciences, a wholly owned subsidiary of Novartis, is letting go of 40 employees, with the cuts happening on a rolling basis beginning Dec. 31.

hubs.li/Q04DrpGh0

Average jobs live on BioSpace increased year over year in October, a good sign for those eyeing a new position. If that’s you, check out the list of which companies are most actively looking to hire.

hubs.ly/Q04DqJJW0

To build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patients.

hubs.li/Q04DqHYK0

Evommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures roiled the biotech’s internal pipeline earlier this year.

hubs.ly/Q04DqDY70

AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.

hubs.ly/Q04DqCg70

On Denatured, Lewis Bender, CEO at Intensity Therapeutics, and Paul-Peter Tak, president, CEO & director at Candel Therapeutics, discuss how intratumoral therapies trigger systemic anticancer immunity via a local injection to reshape immuno-oncology.

hubs.ly/Q04DqBn40

Biotech and pharma professionals share job hunt challenges after being let go, while a recruiting expert discusses why hiring managers prefer candidates without employment gaps and how to address gaps in interviews.

hubs.li/Q04DqlGr0

Ultragenyx is undertaking “substantial headcount and expense reductions,” cutting about 20% of its workforce, as noted in Tuesday’s Q3 earnings report. It’s “entering a new stage focused on commercial execution and a smaller, more targeted R&D footprint.”

hubs.li/Q04DlmbB0

AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.

hubs.li/Q04Dlgcg0

With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjector formulation.

hubs.li/Q04DldP90